Literature DB >> 8254752

Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA.

Y M Zhang1, S C Dawson, D Landsman, H C Lane, N P Salzman.   

Abstract

Human immunodeficiency virus (HIV) virion RNA and proviral DNA sequences have been examined over a 1-year period in an HIV-seropositive patient, commencing with the start of zidovudine treatment. By characterizing the variable V3 and V4 env domains, four related but structurally discrete genotypes could be identified prior to the start of therapy and during the subsequent 60-week period of therapy. Each of the four subtypes showed a unique pattern in the preservation of glycosylation sites. A comparison of the V3 amino acid sequences in peripheral blood mononuclear cell proviral DNA and plasma virion RNA at 0, 24, 36, and 60 weeks demonstrated that proviral DNA did not serve as a predictor of the structure of virion RNA. HIV virion RNA subtype 3 was the most prevalent virion RNA subtype at three of the four periods studied, yet no corresponding proviral DNA was detected. Other virion subtypes have been observed, but only on a transient basis. The present data are consistent with a model of HIV infection in which related but different HIV substrains coexist and evolve independently within an individual. Characterization of virion RNA may be required to identify the unique properties of the virus involved in disease progression; characterization of proviral DNA will not yield this information.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254752      PMCID: PMC236302     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  CLUSTAL V: improved software for multiple sequence alignment.

Authors:  D G Higgins; A J Bleasby; R Fuchs
Journal:  Comput Appl Biosci       Date:  1992-04

2.  Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates.

Authors:  L Q Zhang; P Simmonds; C A Ludlam; A J Brown
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

3.  Genetic variation in AIDS viruses.

Authors:  J M Coffin
Journal:  Cell       Date:  1986-07-04       Impact factor: 41.582

4.  Antigenic diversity thresholds and the development of AIDS.

Authors:  M A Nowak; R M Anderson; A R McLean; T F Wolfs; J Goudsmit; R M May
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

5.  Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers.

Authors:  J Albert; E M Fenyö
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

6.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

7.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.

Authors:  S M Wolinsky; C M Wike; B T Korber; C Hutto; W P Parks; L L Rosenblum; K J Kunstman; M R Furtado; J L Muñoz
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

8.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.

Authors:  P Simmonds; L Q Zhang; F McOmish; P Balfe; C A Ludlam; A J Brown
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Evolution of human immunodeficiency virus type 1 nucleotide sequence diversity among close contacts.

Authors:  H Burger; B Weiser; K Flaherty; J Gulla; P N Nguyen; R A Gibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

10.  Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy.

Authors:  M Semple; C Loveday; I Weller; R Tedder
Journal:  J Med Virol       Date:  1991-09       Impact factor: 2.327

View more
  15 in total

1.  Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.

Authors:  E L Delwart; H Pan; H W Sheppard; D Wolpert; A U Neumann; B Korber; J I Mullins
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy.

Authors:  N Koch; N Yahi; F Ariasi; J Fantini; C Tamalet
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.

Authors:  D V Havlir; S Eastman; A Gamst; D D Richman
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

Authors:  B T Korber; K MacInnes; R F Smith; G Myers
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

5.  Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection.

Authors:  J A Nelson; F Baribaud; T Edwards; R Swanstrom
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

Authors:  M Nijhuis; C A Boucher; P Schipper; T Leitner; R Schuurman; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

Authors:  Shigeyoshi Harada; Kazuhisa Yoshimura; Aki Yamaguchi; Samatchaya Boonchawalit; Keisuke Yusa; Shuzo Matsushita
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.

Authors:  Gustavo H Kijak; Viviana Simon; Peter Balfe; Jeroen Vanderhoeven; Sandra E Pampuro; Carlos Zala; Claudia Ochoa; Pedro Cahn; Martin Markowitz; Horacio Salomon
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.